RxDoctor Payments DataLook up a doctor →

Ricardo Ayala, MD

Neurology · Tallahassee, FLNPI 1699742767

Payments from drug & device makers

$6,685,289in general payments, 2019–2025

Across 1,066 payments — averaging $6271.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3.9M
  • Eli Lilly$2.5M
  • Biogen$105K
  • UCB SA$40K
  • EMD Serono, Inc.$25K
  • Neurocrine Biosciences, Inc.$13K
  • plus $33K from 54 others
$243,782in research payments, 2019–2025

Across 7 payments — averaging $34,826 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$244K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis115$3,947,930
Eli Lilly16$2,521,984
Biogen37$105,032
UCB SA4$40,090
EMD Serono, Inc.50$24,600
Neurocrine Biosciences, Inc.16$12,834
Jazz Pharmaceuticals Inc.48$12,298
Pfizer28$7,302
AbbVie(2 entities)113$1,527
SK Life Science, Inc.65$1,310
UCB, Inc.41$886
Greenwich Biosciences, Inc.36$865
Amgen(2 entities)44$701
Supernus Pharmaceuticals, Inc.76$694
Neurelis, Inc.36$654
Lilly USA, LLC31$639
Eisai Inc.24$527
Teva Pharmaceuticals USA, Inc.34$503
Janssen Research & Development, LLC2$372
E.r. Squibb & Sons, L.L.C.7$371
AstraZeneca19$357
Genentech USA, Inc.20$295
Catalyst Pharmaceuticals, Inc.16$263
MDD US Operations, LLC15$261
Sunovion Pharmaceuticals Inc.24$230
Lundbeck LLC14$219
Acadia Pharmaceuticals Inc11$183
TG Therapeutics, Inc.4$175
Argenx US, Inc.7$175
Bristol Myers Squibb10$170
Kyowa Kirin, Inc.9$161
Sanofi10$156
Biohaven Pharmaceutical Holding Company Ltd.9$149
CSL Behring8$147
Tanabe Pharma America, Inc.7$113
Genentech, Inc.1$105
Strongbridge US Inc.7$92
GE HealthCare4$81
Mallinckrodt Enterprises LLC5$81
Otsuka America Pharmaceutical, Inc.4$79
Acorda Therapeutics, Inc4$72
Johnson & Johnson(2 entities)3$61
Banner Life Sciences, LLC3$60
Adamas Pharmaceuticals, Inc.4$52
Axsome Therapeutics, Inc.2$50
Biohaven Pharmaceuticals, Inc.3$45
Almatica Pharma LLC3$40
Avion Pharmaceuticals2$40
Mallinckrodt Hospital Products Inc.2$40
Boston Scientific2$29
Azurity Pharmaceuticals, Inc.1$25
Upsher-smith Laboratories LLC1$22
Medtronic1$21
Nevro Corp.1$19
Grifols USA, LLC1$19
Xeris Pharmaceuticals, Inc.1$18
Sanofi-aventis U.S. LLC1$16
Harmony Biosciences LLC1$14
Merck1$14
Portola Pharmaceuticals, LLC1$13

How this compares

$6,685,289 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$91,218
Medicare patients
312
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Tallahassee

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →